BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18493158)

  • 1. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
    Manzione L; Romano R; Germano D
    Oncology; 2007; 73(5-6):311-5. PubMed ID: 18493158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
    Verderame F; Russo A; Di Leo R; Badalamenti G; Santangelo D; Cicero G; Valerio MR; Gulotta G; Tomasello G; Gebbia N; Fulfaro F
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii68-72. PubMed ID: 16760298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
    Jang JS; Lim HY; Hwang IG; Song HS; Yoo N; Yoon S; Kim YH; Park E; Byun JH; Lee MA; Oh SJ; Lee KH; Kim BS; Oh SC; Kim SY; Lee SJ
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):641-7. PubMed ID: 19652971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
    Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
    Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
    Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
    Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.
    Kim HJ; Lee NS; Lee SC; Bae SB; Kim CK; Cheon YG; Kim YS; Moon JH; Cho YD; Park SH; Lee KT; Park SK; Won JH; Park HS; Hong DS
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):371-7. PubMed ID: 19142638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
    Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
    Graham JS; Boyd K; Coxon FY; Wall LR; Eatock MM; Maughan TS; Highley M; Soulis E; Harden S; Bützberger-Zimmerli P; Evans TR
    BMC Res Notes; 2016 Mar; 9():161. PubMed ID: 26969121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
    Gruenberger B; Schueller J; Heubrandtner U; Wrba F; Tamandl D; Kaczirek K; Roka R; Freimann-Pircher S; Gruenberger T
    Lancet Oncol; 2010 Dec; 11(12):1142-8. PubMed ID: 21071270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
    Li J; Merl M; Lee MX; Kaley K; Saif MW
    Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
    André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
    Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas.
    Halim A; Ebrahim MA; Saleh Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):217-24. PubMed ID: 21062755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.
    André T; Reyes-Vidal JM; Fartoux L; Ross P; Leslie M; Rosmorduc O; Clemens MR; Louvet C; Perez N; Mehmud F; Scheithauer W
    Br J Cancer; 2008 Sep; 99(6):862-7. PubMed ID: 19238628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.
    Hollebecque A; Bouché O; Romano O; Scaglia E; Cattan S; Zerbib P; Heurgue A; Lagarde S; Mariette C; Triboulet JP; Pruvot FR; Hebbar M
    Chemotherapy; 2010; 56(3):234-8. PubMed ID: 20551640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
    Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
    Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
    Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
    Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Roviello F; Marrelli D; Francini E
    Anticancer Drugs; 2015 Jul; 26(6):682-6. PubMed ID: 25811963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2.
    Mir O; Coriat R; Dhooge M; Perkins G; Boudou-Rouquette P; Brezault C; Ropert S; Durand JP; Chaussade S; Goldwasser F
    Anticancer Drugs; 2012 Aug; 23(7):739-44. PubMed ID: 22700002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.